ABBOTT-CLOPIDOGREL TABLET

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

CLOPIDOGREL (CLOPIDOGREL BISULFATE)

Disponível em:

ABBOTT LABORATORIES, LIMITED

Código ATC:

B01AC04

DCI (Denominação Comum Internacional):

CLOPIDOGREL

Dosagem:

75MG

Forma farmacêutica:

TABLET

Composição:

CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75MG

Via de administração:

ORAL

Unidades em pacote:

100/500

Tipo de prescrição:

Prescription

Área terapêutica:

PLATELET AGGREGATION INHIBITORS

Resumo do produto:

Active ingredient group (AIG) number: 0134440001; AHFS:

Status de autorização:

CANCELLED POST MARKET

Data de autorização:

2015-12-31

Características técnicas

_ _
_Abbott-Clopidogrel Product Monograph _
_Page 1 of 52 _
_ _
_ _
PRODUCT MONOGRAPH
PR
ABBOTT-CLOPIDOGREL
Clopidogrel Tablets USP
75 mg clopidogrel, as clopidogrel bisulfate
Platelet Aggregation Inhibitor
Abbott Laboratories, Limited
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Revision:
November 27, 2014
Submission Control No.: 179756
_ _
_Abbott-Clopidogrel Product Monograph _
_Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.......................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
.........................................................